Cardiazol-induced seizures as a treatment for schizophrenia

Where in the source: Google Books, bibliographic information: Board of Control report, H.M. Stationery Office, 1938

Bibliographic record of the Board of Control’s official 1938 report on Cardiazol and hypoglycaemic shock treatment. The catalogue establishes publication details; the full report was not inspected and this record does not prove hospital adoption.

Where in the source: HC Deb, 14 July 1938, vol. 338, cols. 1515–1516, question 62 and Mr Elliot’s reply

Primary parliamentary record confirming that the Board of Control was preparing a report on Cardiazol treatment. The minister said publication was imminent; this announcement does not establish treatment outcomes or hospital adoption.

Where in the source: McCrae (2006), pp. 72–78, 83–86; full text deposited as HAL hal-00570852

Peer-reviewed historical analysis describing Cardiazol as the most widely used major somatic treatment in British public mental hospitals in the late 1930s, tracing the dubious biological-antagonism hypothesis, flawed outcome measurement, severe fear and the transition away from Cardiazol. Full text is available as HAL deposit hal-00570852; modern ECT indications are sourced separately.

Where in the source: McCrae (2006), pp. 70–71 (diffusion), 75 (behavioral outcomes), 77–78 (fractures and memory), 78–79 (fear)

The article documents diffusion, fear, fractures and memory disturbance, including reports of amnesia months later. These are treatment risks reported across institutions, not Bexley-specific incidence figures. Contemporary claims about structural brain injury were contested; the record therefore states the reported memory effects.

Where in the source: McCrae (2006), pp. 83–84, Electroshock

The attributed 1941 change in conception and later replacement by ECT provide a history of clinical change. Continued use in named hospitals rules out treating 1941 as general cessation; these passages do not document a corrective act by the Board or Bexley.

Where in the source: Freebody, chapter 6, The Views of Psychiatrists in Paris and London, paragraph with notes 63–66

Modern historical synthesis identifying Cardiazol as the most widely used somatic treatment for schizophrenia and affective disorders in British public mental hospitals and noting that the Maudsley barred trials because the induced convulsions caused extreme anxiety and fear.

Where in the source: McCrae (2006), pp. 70–71, 74 (quoting Board of Control, 1939, p. 38), 86 note 1

Bexley’s dedicated ward and June 1937 start are identified. The Board’s published justification for continuing available shock methods is quoted through this history, not from a directly inspected annual report; it does not prove official endorsement of antagonism.

Where in the source: Cook (1938), pp. 570, 573–574, especially Table III and its discussion

Bexley’s own clinical report describes completed courses and the staff’s confidence in Cardiazol. The original paper also records the author’s doubt about antagonism on p. 567.

Where in the source: McCrae (2006), pp. 70–71, 74

The dedicated ward, official investigation, publication, survey and recommendation to continue available methods establish distinct clinical and administrative channels. RMPA discussion included opposition, so it is not treated as association endorsement.

Where in the source: Cook (1938), pp. 568 (Course), 573–574 (Bexley practice and results)

Cook describes repeated treatment courses, selection of patients and the clinical claims used to justify Bexley’s practice. This establishes hospital adoption without assigning the same regimen to every surveyed institution.

Where in the source: Cook (1938), p. 567 (doubt about theory), pp. 568–571 (procedure, risks and distress), 572–574 (evaluation and Bexley series)

The original report directly describes induced generalized seizures, patients’ fear and problems in comparing remission figures. Its observed outcomes and confident interpretations must be distinguished from controlled proof of efficacy. Page 567 explicitly questions the theory despite clinical adoption.

Where in the source: Finkelman, Steinberg and Liebert (1938), JAMA 110(10):706–709, abstract

Contemporary 1938 clinical paper explicitly states Meduna's theory that schizophrenia and epilepsy were biologically antagonistic and describes attempts to cause remission by inducing epileptiform seizures with Metrazol. The inspected abstract describes an American series, not British institutional endorsement.

Where in the source: Qin et al. (2005), Results and Discussion

The Danish register cohort documents schizophrenia following epilepsy and an increased associated risk. This contradicts mutual exclusion, but the observational study neither tests Cardiazol nor proves causation; its analyses use inpatient diagnoses.

Where in the source: NG222, final recommendations 1.13.1–1.13.4

NICE gives specified circumstances for considering ECT in severe depression, including rapid response and failed other treatments, together with risk and consent requirements. This is modern ECT guidance, not evidence for historical chemical convulsions.

Where in the source: TA59, final recommendations 1.1–1.4 and 1.9

Final guidance restricts ECT for catatonia to specified severe circumstances and does not recommend it for general schizophrenia management. TA59’s depression guidance has been superseded by NG222; the two sources have distinct scopes.